Home Tags GBM

Tag: GBM

In the War Against Brain Cancer, Accelerated Clinical Trials Are a...

More than 1.4 million people live with malignant brain tumors. Glioblastoma – the cancer that killed Senators John McCain and Ted Kennedy – is...

ASCO 2016 Emphasizes Collective Wisdom: The Future of Patient-Centered Care and...

Only a few weeks until the start of the 2016 annual meeting of the American Society of Clinical Oncology (ASCO). This year’s ASCO, taking...

Randomized Phase I Trial Results of ABT-414 In Patients with Glioblastoma...

Updated interim results from a Phase I clinical trial of ABT-414 (AbbVie) in patients with glioblastoma multiforme (GBM), an aggressive form of brain cancer,...
ESMO 2014 Congress - Madrid, Spain

Initial Phase I Trial Results of anti-EGFR drug ABT-414 in the...

With a median survival between 1 and 2 years and no long-term curative treatments, the management of patients with Glioblastoma Multiforme (GBM), the most common and most aggressive type of malignant primary brain tumor, remains challenging.
FDA_EMA

Phase I Trial Results in GBM Lead to Orphan Drug Designation...

The European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA) have granted orphan drug designation to AbbVie's investigational compound ABT-414, an anti-epidermal growth factor receptor antibody drug conjugate, which is being evaluated for safety and efficacy in patients with glioblastoma multiform.
ASCO 50th Annual Meeting

Phase I Study of ABT-414 Shows Four Objective Responses, Including Complete...

Preliminary results from an ongoing Phase I study with the investigational compound ABT-414 (Abbvie, Inc.,North Chicago, Illinois, U.S.A.), an anti-epidermal growth factor receptor (EGFR) monoclonal antibody drug conjugate or ADC, in combination with temozolomide (Temodar®; Merck & Co., Inc.) which is indicated for the treatment of adult patients with newly diagnosed glioblastoma multiforme concomitantly with radiotherapy and then as maintenance treatment, showed four objective responses, including one complete response, in patients with recurrent or unresectable glioblastoma multiform. In separate clinical trials ABT-414 is also investigated for the treatment of patients with squamous cell tumors.

FEATURED RESOURCES